Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus endocrine therapy versus chemotherapy-based strategy in HR-positive/HER2-negative metastatic breast cancer
2016-004482-89Phase 4Completed
- Sponsor
- GBG Forschungs
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Time-to-treatment failure. Started Aug 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004482-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004482-89.